Systemic regimens
GI oncology
Developers advancing systemic regimens in pancreatic and gastrointestinal cancers seeking a dedicated local-control component.
Where we partner
Delivery & dosimetry
Radiopharma
Radiopharmaceutical and radiotherapeutics platforms with complementary delivery, isotope or dosimetry capabilities.
Next-generation backbones
Targeted therapy
Programmes building next-generation targeted backbones designed to combine with a backbone-agnostic local therapeutic.
Platform & intellectual property
Intellectual
property
BetaGlue Therapeutics holds a wholly-owned intellectual property estate across multiple jurisdictions, with granted patents in the United States, Europe and Canada and pending filings covering composition of matter, product by process and medical use claims — spanning the device, the delivery system and the radioactive microspheres. The company also owns a substantial body of know-how.
Beyond its lead indication in locally advanced pancreatic cancer, YntraDose has platform potential across multiple solid tumors.